enGene Therapeutics Inc. (ENGN)

In the past six months, enGene Therapeutics Inc.'s stock has trended down. The company changed its name from enGene Holdings Inc. to enGene Therapeutics Inc. Financial results for First Quarter 2026 and Full Year 2025 were reported, impacting the stock price. enGene participated in several investor conferences. The company announced an expanded debt facility with Hercules Capital, Inc. Recent SEC filings include a $100M ATM share program launch and the termination of a previous deal, and a 10-Q filing detailing Q1 loss and LEGEND trial data. Preliminary data from the LEGEND pivotal cohort was provided in November 2025, with an update planned for spring 2026 and 12-month complete response data expected in the second half of 2026. A Biologics License Application submission for detalimogene is planned for the second half of 2026.

The demand for enGene Therapeutics Inc.'s products and services is not subject to typical consumer demand seasonality. Demand will primarily be driven by the successful progression of its clinical trials, regulatory approvals, and the medical need for its therapeutic solutions.

enGene Therapeutics, Inc. is a clinical-stage biotechnology company focused on delivering genetic medicines to mucosal tissues and other organs. The company operates in the Healthcare sector, specifically in the Biotechnology industry, focusing on Bio Therapeutic Drugs and Medical Research. Their primary product candidate is detalimogene voraplasmid, a non-viral gene therapy for high-risk non-muscle invasive bladder cancer. Detalimogene has received Regenerative Medicine Advanced Therapy and Fast Track designations from the U.S. FDA for BCG-unresponsive CIS NMIBC, and has been selected for the FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program.

enGene Therapeutics Inc. is headquartered in Saint-Laurent, Quebec, Canada, and has a corporate office in Boston, Massachusetts, USA. The company's LEGEND Phase 2 trial for detalimogene is enrolling patients across sites in the USA, Canada, Europe, and the Asia-Pacific region.

enGene Therapeutics Inc. holds a "Moderate Buy" consensus rating from analysts, with a significant upside potential from its current price. The company has been the subject of research reports, indicating strong analyst interest. The company's news sentiment score is 0.18. The recent name change to enGene Therapeutics Inc. signals the company's progress and its strategic transition towards becoming a commercial organization.

Private equity firms hold approximately 38% of the company's shares, while institutional ownership stands at about 35%, and the general public owns a 16% stake. Major institutional shareholders include Forbion Capital Partners Management Holding BV, Perceptive Advisors LLC, VR Adviser, LLC, Kynam Capital Management, LP, and Deep Track Capital, LP, among others.